James B. Kahn

3.8k total citations
61 papers, 3.0k citations indexed

About

James B. Kahn is a scholar working on Epidemiology, Pharmacology and Molecular Medicine. According to data from OpenAlex, James B. Kahn has authored 61 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 28 papers in Pharmacology and 15 papers in Molecular Medicine. Recurrent topics in James B. Kahn's work include Antibiotics Pharmacokinetics and Efficacy (26 papers), Pneumonia and Respiratory Infections (22 papers) and Antibiotic Resistance in Bacteria (15 papers). James B. Kahn is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (26 papers), Pneumonia and Respiratory Infections (22 papers) and Antibiotic Resistance in Bacteria (15 papers). James B. Kahn collaborates with scholars based in United States, Belgium and Netherlands. James B. Kahn's co-authors include Yolanda Mauriz, Clyde Thornsberry, George L. Drusano, Alan M. Tennenberg, Daniel F. Sahm, Barbara A. Wiesinger, Jim Xiang, ‏Mohammed ‏Khashab, Mark E. Jones and Mohammed M. Khashab and has published in prestigious journals such as Journal of Clinical Investigation, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

James B. Kahn

58 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James B. Kahn United States	27	1.9k	1.4k	1.1k	420	367	61	3.0k
L. Verbist Belgium	29	1.0k 0.6×	1.1k 0.8×	686 0.7×	173 0.4×	894 2.4×	127	2.7k
Ian R. Friedland United States	35	2.7k 1.4×	2.0k 1.4×	1.8k 1.7×	840 2.0×	565 1.5×	78	4.6k
Nathalie Dartois France	21	851 0.5×	902 0.6×	1.2k 1.1×	403 1.0×	587 1.6×	30	2.5k
Olaf Burkhardt Germany	27	1.0k 0.5×	728 0.5×	390 0.4×	266 0.6×	422 1.1×	56	2.1k
C H Nightingale United States	26	962 0.5×	1.2k 0.9×	576 0.5×	205 0.5×	660 1.8×	70	2.3k
Mark H. Gotfried United States	34	1.3k 0.7×	1.2k 0.8×	988 0.9×	202 0.5×	441 1.2×	87	3.4k
You-ning Liu China	27	857 0.5×	585 0.4×	826 0.8×	189 0.5×	565 1.5×	89	2.4k
J. Caillon France	32	1.0k 0.5×	689 0.5×	759 0.7×	241 0.6×	958 2.6×	192	3.4k
Giannoula S. Tansarli United States	24	1.0k 0.5×	828 0.6×	1.4k 1.3×	674 1.6×	319 0.9×	50	2.5k
Kingsley Coulthard Australia	18	985 0.5×	1.6k 1.1×	2.3k 2.2×	237 0.6×	163 0.4×	37	3.1k

Countries citing papers authored by James B. Kahn

Since Specialization

Citations

This map shows the geographic impact of James B. Kahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James B. Kahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James B. Kahn more than expected).

Fields of papers citing papers by James B. Kahn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James B. Kahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James B. Kahn. The network helps show where James B. Kahn may publish in the future.

Co-authorship network of co-authors of James B. Kahn

This figure shows the co-authorship network connecting the top 25 collaborators of James B. Kahn. A scholar is included among the top collaborators of James B. Kahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James B. Kahn. James B. Kahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kahn, James B., Ronald Witteles, Kenneth W. Mahaffey, et al.. (2017). A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction. Advances in Medical Education and Practice. Volume 8. 559–566. 5 indexed citations

Kahn, James B., et al.. (2009). Switching to Aripiprazole in Outpatients with Schizophrenia Experiencing Insufficient Efficacy and/or Safety/Tolerability Issues with Risperidone: A Randomized, Multicentre, Open-label Study. Pharmacopsychiatry. 42(3). 114–121. 22 indexed citations

Ambrose, Paul G., Jack B. Anon, Sujata M. Bhavnani, et al.. (2008). Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. Diagnostic Microbiology and Infectious Disease. 61(1). 13–20. 13 indexed citations

Peterson, Janet, Simrati Kaul, ‏Mohammed ‏Khashab, Alan C. Fisher, & James B. Kahn. (2007). Identification and Pretherapy Susceptibility of Pathogens in Patients with Complicated Urinary Tract Infection or Acute Pyelonephritis Enrolled in a Clinical Study in the United States from November 2004 Through April 2006. Clinical Therapeutics. 29(10). 2215–2221. 26 indexed citations

Klausner, Howard, Patricia D. Brown, Janet Peterson, et al.. (2007). A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Current Medical Research and Opinion. 23(11). 2637–2645. 67 indexed citations

Shorr, Andrew F., Mohammed M. Khashab, Jim Xiang, Alan M. Tennenberg, & James B. Kahn. (2006). Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respiratory Medicine. 100(12). 2129–2136. 32 indexed citations

Khashab, Mohammed M., Jim Xiang, & James B. Kahn. (2006). Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Current Medical Research and Opinion. 22(10). 1997–2006. 17 indexed citations

Anon, Jack B., et al.. (2006). Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. Diagnostic Microbiology and Infectious Disease. 57(1). 105–107. 11 indexed citations

Grossman, Ronald F., et al.. (2006). Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: A post hoc analysis of data from severely ill patients. Clinical Therapeutics. 28(8). 1175–1180. 8 indexed citations

10.

Drusano, George L., Sandra L. Preston, Cynthia L. Fowler, et al.. (2004). Relationship between Fluoroquinolone Area under the Curve:Minimum Inhibitory Concentration Ratio and the Probability of Eradication of the Infecting Pathogen, in Patients with Nosocomial Pneumonia. The Journal of Infectious Diseases. 189(9). 1590–1597. 197 indexed citations

11.

Kahn, James B., et al.. (2004). Cumulative Clinical Trial Experience with Levofloxacin for Patients with Community-Acquired Pneumonia-Associated Pneumococcal Bacteremia. Clinical Infectious Diseases. 38(Supplement_1). S34–S42. 11 indexed citations

12.

West, Mike, Bernard R. Boulanger, Charles Fogarty, et al.. (2003). Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study. Clinical Therapeutics. 25(2). 485–506. 89 indexed citations

13.

Jumbe, Nelson L. ‘Shasha’, Arnold Louie, Robert Leary, et al.. (2003). Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. Journal of Clinical Investigation. 112(2). 275–285. 201 indexed citations

14.

Peipert, Jeffrey F., et al.. (1999). Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis). Infectious Diseases in Obstetrics and Gynecology. 7(3). 138–144. 13 indexed citations

15.

Adelglass, Jeffrey, Terry M. Jones, Gary Ruoff, et al.. (1998). A Multicenter, Investigator‐Blinded, Randomized Comparison of Oral Levofloxacin and Oral Clarithromycin in the Treatment of Acute Bacterial Sinusitis. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(6). 1255–1263. 41 indexed citations

16.

File, Thomas M., John G. Bartlett, Gail H. Cassell, et al.. (1997). THE IMPORTANCE OF CHLAMYDIA PNEUMONIAE AS A PATHOGEN. Infectious Diseases in Clinical Practice. 6(Supplement 2). S28–S31. 8 indexed citations

17.

Madsen, Paul O., G.H. Malek, & James B. Kahn. (1995). Single Dose UTI Prophylaxis in Transurethral Surgery. Drugs. 49(Supplement 2). 480–482. 1 indexed citations

18.

Peterson, Lance R., et al.. (1995). In Vitro Activity of Ofloxacin, Ciprofloxacin, and Cefoperazone Alone and in Combination against Xanthomonas maltophilia. Drugs. 49(Supplement 2). 246–249. 1 indexed citations

19.

Kahn, James B., et al.. (1972). Surveillance of Legal Abortions in the United States, 1970. Journal of Obstetric, Gynecologic & Neonatal Nursing. 1. 17–27. 1 indexed citations

20.

Kahn, James B., et al.. (1964). THE MECHANISM OF THE VASODEPRESSOR RESPONSE TO TYRAMINE IN DOGS. Journal of Pharmacology and Experimental Therapeutics. 145(3). 292–298. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact